JAN 07, 2020: Bristol-Myers Squibb Company announced that it has completed its previously announced divestment of its oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy, to Catalent Inc.
The divestiture is a part of Bristol-Myers Squibb’s strategy to make simpler and to realign its business portfolio to address changes in its business and the future desires of its evolving pipeline.
The Anagni facility manufactures and the packages cardiovascular, anticancer, metabolic and anti-inflammatory medicines as well as non-penicillin-based antibiotics, antivirals, analgesics as the injectables and biologics.
The Company is now focusing resources on its highest priorities of discovering, developing and delivering transformational medicines for the patients facing serious diseases. https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-completes-divestment-manufacturing-facili